Table 1.
Gender, age, and serum CCL2 levels of the study subjects. (Individual patient data is shown in Additional file 1: Table S1)
| Number of Patients | Gender | Age | Serum CCL2 (pg/ml) | ||
|---|---|---|---|---|---|
| Women | Men | ||||
| Unexposed (no apparent disease) | 41 | 10 | 31 | 56.0 ± 20.0 | 275.2 ± 98.2 |
| Possibly Exposed (no apparent disease) | 356 | 33 | 323 | 68.7 ± 8.3 | 307.5 ± 117.7 |
| Mesothelioma (all patients) | 50 | 5 | 45 | 72.5 ± 8.6 | 421.3 ± 295.1a,b |
| Mesothelioma (stage 1 patients) | 12 | 0 | 12 | 72.8 ± 9.1 | 289.9 ± 115.4 |
| Mesothelioma (stage 2 patients) | 5 | 0 | 5 | 75.6 ± 7.1 | 281.0 ± 111.2 |
| Mesothelioma (stage 3 patients) | 14 | 1 | 13 | 74.3 ± 10.7 | 486.0 ± 333.4c,d |
| Mesothelioma (stage 4 patients) | 19 | 4 | 15 | 70.2 ± 6.8 | 493.5 ± 346.7c,d |
aDifferent from the Unexposed (no apparent disease) group at p < 0.01
bDifferent from the Possibly Exposed (no apparent disease) group at p < 0.05
cDifferent from the Unexposed (no apparent disease) and the Possibly Exposed (no apparent disease) groups at p < 0.001
dDifferent from the Mesothelioma (stage 1 patients) group at p < 0.01